|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
It was previously reported that follistatin-like 3(FSTL3), an activin A binding protein, contributes to the invasion and migration of trophoblast.
|
31810141 |
2020 |
|
Takayasu Arteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Considering this, we further built a logistic regression model based on multiple cytokines, including CA (cancer antigen) 125, FLRG (follistatin-related protein), IGFBP (insulin-like growth factor-binding protein)-2, CA15-3, GROa (growth-regulated alpha protein), LYVE (lymphatic vessel endothelial hyaluronic acid receptor)-1, ULBP (UL16-binding protein)-2, and CD (cluster of differentiation) 99, with an area under the curve reaching 0.909 for discriminating TA activity status.
|
30645172 |
2019 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We compared circulating levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like [FSTL]3, activin B), c) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy associated plasma protein [PAPP]-A) in two studies: a) 18 individuals with early stage NAFLD vs. 14 controls (study 1; early NAFLD study) and in b) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs. 50 controls (24 lean and 26 obese) (study 2).
|
31690932 |
2020 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Follistatin-related protein gene (FRP) is expressed in the synovial tissues of rheumatoid arthritis, but its polymorphisms are not associated with genetic susceptibility.
|
15638044 |
2005 |
|
Rheumatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
As a result of this unique combination of the libraries and probes, we cloned follistatin-related protein (FRP) as a novel autoantigen in systemic rheumatic diseases.
|
9786430 |
1998 |
|
Renal Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
In both human CKD and AKD, renal dysfunction remained the strongest independent predictor of FSTL3 serum concentrations in multivariate analyses.
|
28339962 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations.
|
11757036 |
2002 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In more advanced stages, FSTL3 levels are higher in NASH compared to SS and, within NAFLD patients, in those with more severe lobular and portal inflammation.
|
31690932 |
2020 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our data provide strong evidence that endogenous FLRG contributes to tumor cell proliferation through antagonizing endogenous activin effects.
|
17671190 |
2007 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01).
|
28178680 |
2017 |
|
Metabolic Syndrome X
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Activin A, activin B, follistatin, and FSTL3 were measured in (1) 80 subjects divided according to age (young vs old) and fitness status (active vs sedentary) before and after exercise at 70% maximal oxygen consumption (VO2max), followed by 90% of VO2max until exhaustion; and (2) 23 subjects [9 healthy and 14 with metabolic syndrome (MetS)] who completed four sessions: no exercise, high-intensity interval exercise, continuous moderate-intensity exercise, and resistance exercise for up to 45 minutes.
|
30085147 |
2018 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth.
|
17671190 |
2007 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations.
|
11757036 |
2002 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer.
|
30388235 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that activin-induced growth inhibition is altered in FLRG-expressing breast cancer lines.
|
17671190 |
2007 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Expression levels of follistatin, follistatin-like 3, and activin subunits beta(A) as well as beta(E) were investigated in chemically induced rat and human liver tumours by real-time PCR and immunohistochemistry.
|
16935389 |
2006 |
|
Limb ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
When iPS-ECs overexpressing FSTL3 were subcutaneously injected in in vivo angiogenic model or intramuscularly injected in a hind limb ischemia NOD.CB17-Prkdcscid/NcrCrl SCID mice model, FSTL3 significantly induced angiogenesis and blood flow recovery, respectively.
|
29569797 |
2018 |
|
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.
|
28178680 |
2017 |
|
Heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
|
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
|
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
|
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There were no significant differences in serum FSTL3 levels (p = 0.578) between the GDM group and the GDM-free control group.
|
27623975 |
2017 |
|
Fetal Growth Retardation
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that IGFBP1 and Follistatin-like 3 are highly up-regulated in IUGR in the placenta.
|
16338475 |
2006 |